Low dose DEC as an alternative to current dose used in Lymphatic Filariasis program

Efficacy and adverse reactions of single dose DEC of 100 mg, 200 mg and 300 mg strength in filariasis endemic community in Orissa

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2014/02/004375

Enrollment

900

Registered

2014-02-03

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Arm 2: DEC 200 mg to all age groups above 5 years single dose annual orally for 5 annual rounds. Total 5 doses in 5 years. Intervention2: Arm 1: DEC 100 mg to all age groups above 5 yea

Eligibility

Inclusion criteria

Inclusion criteria: More than 5 years one site regimen consisting 100 mg DEC second site regimen consisting of 200 mg DEC and third site regimen consisting of 300 mg DEC annually oral single dose for 2 to 5 years child all sites given 100 mg DEC annually oral single dose

Exclusion criteria

Exclusion criteria: More than 2 yrs, pregnant women, seriously ill subjects

Design outcomes

Primary

Measure	Time frame
1. To compare the efficacy of single dose DEC of 100mg strength in mf suppression with either 200mg or 300mg given uniformly in all age groups as annual doses of MDA in 3 different endemic communities. 2. To compare the frequency and intensity of side reaction of DEC observed with three different strengths given as annual dose of MDA. 3. To observe the effect on vector transmission in three different communities following annual uniform doses of DEC of varied strength. Timepoint: Baseline, 4, 12, 24, 36, 48 and 60 months	—

Measure

Time frame

1. To compare the efficacy of single dose DEC of 100mg strength in mf suppression with either 200mg or 300mg given uniformly in all age groups as annual doses of MDA in 3 different endemic communities. 2. To compare the frequency and intensity of side reaction of DEC observed with three different strengths given as annual dose of MDA. 3. To observe the effect on vector transmission in three different communities following annual uniform doses of DEC of varied strength. Timepoint: Baseline, 4, 12, 24, 36, 48 and 60 months

—

Secondary

Measure	Time frame
a) Mf suppression effect of 100mg, 200mg or 300mg DEC given as single annual dose of MDA. b) Effect on community load of microfilarimia c) Effect of low dose DEC of 100 mg compared to either 200 or 300mg in higher age groups 6-14 or above 14 yrs. Timepoint: Baseline, 4, 12, 24, 36, 48 and 60 months	—

Countries

India

Contacts

Public ContactDr Bhagirathi Dwibedi

Regional Medical research Centre ICMR Chandrasekharpur Bhubaneswar

bhagirathidwibedi@yahoo.com06742301332

Outcome results